Management of coronary artery disease via simvastatin-loaded novasomes.
AG, F., A, B., O, Y.G., R, A.B., F, A.A.S., & FI, A.E.E. (2026). Management of coronary artery disease via simvastatin-loaded novasomes.. Journal of microencapsulation. https://doi.org/10.1080/02652048.2026.2688996
AG F, A B, O YG, R AB, F AAS, FI AEE. Management of coronary artery disease via simvastatin-loaded novasomes.. Journal of microencapsulation. 2026; doi: 10.1080/02652048.2026.2688996
AG F, A B, O YG, et al. Management of coronary artery disease via simvastatin-loaded novasomes.[J]. Journal of microencapsulation. 2026. DOI: 10.1080/02652048.2026.2688996.
@article{ag2026,
author = {Fouad AG and Belal A and Yousef Gushgari O and Ahmed Bawaked R and Abdullah Al Shwail F and Abo El-Ela FI},
title = {Management of coronary artery disease via simvastatin-loaded novasomes.},
journal = {Journal of microencapsulation},
year = {2026},
doi = {10.1080/02652048.2026.2688996},
note = {PMID: 42341093},
}
TY - JOUR AU - Fouad AG AU - Belal A AU - Yousef Gushgari O AU - Ahmed Bawaked R AU - Abdullah Al Shwail F AU - Abo El-Ela FI TI - Management of coronary artery disease via simvastatin-loaded novasomes. T2 - Journal of microencapsulation PY - 2026 DO - 10.1080/02652048.2026.2688996 AN - PMID:42341093 ER -
BACKGROUND: Simvastatin (SMT) offers protection against diabetes mellitus related to coronary artery disease (DM-CAD) because of its cardioprotective, antioxidant, and anti-inflammatory effects. However, its low bioavailability and poor solubility limit its effectiveness. OBJECTIVE: This research aimed to develop and evaluate a nasal simvastatin-loaded novasomes (S-NOV) to enhance the drug's bioavailability, solubility, and effectiveness in treating DM-CAD. METHODS: The efficacy and bioavailability of the nasal S-NOV formulation were tested in a DM-CAD-induced rat model. RESULTS: The optimal S-NOV formulation demonstrated an 8.31-fold increase in bioavailability, a 4.64-fold enhancement in permeability, and a 4.71-fold increase in drug release. The nasal S-NOV formulation showed superior cardioprotective and antioxidant effects compared to oral SMT in various biomarkers, including lactate dehydrogenase, glutathione, and catalase. Histopathological and toxicology studies confirmed that the nasal S-NOV formulation was effective and safe. CONCLUSION: These findings suggest that nasal S-NOV formulation could be a viable and safe therapy for DM-CAD.